NASDAQ: DRIODariohealth Corp Stock
$6.02+0.22 (+3.79%)
Updated Oct 6, 2026
DRIO Price
$6.02
Fair Value Price
N/A
Market Cap
$58.99M
52 Week Low
$5.80
52 Week High
$16.55
P/E
-0.98x
P/B
1.07x
P/S
2.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.00M
Earnings
-$35.67M
Gross Margin
58.2%
Operating Margin
-146.08%
Profit Margin
-215.6%
Debt to Equity
0.75
Operating Cash Flow
-$25M
Beta
1.03
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DRIO Overview
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DRIO's potential to beat the market
- DRIO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
DRIO
RankedUnranked of 39
RankedUnranked of 39
Be the first to know about important DRIO news, forecast changes, insider trades & much more!
DRIO News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DRIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DRIO is good value based on its book value relative to its share price (1.07x), compared to the US Diagnostics & Research industry average (4.68x)
P/B vs Industry Valuation
DRIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DRIO due diligence checks available for Premium users.
Valuation
DRIO fair value
Fair Value of DRIO stock based on Discounted Cash Flow (DCF)
Price
$6.02
Fair Value
-$6.69
Undervalued by
189.98%
DRIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DRIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.98x
Industry
9.74x
Market
51.93x
DRIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.07x
Industry
4.68x
DRIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRIO's financial health
Profit margin
Revenue
$5.2M
Net Income
-$7.9M
Profit Margin
-153.1%
DRIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DRIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$96.6M
Liabilities
$41.5M
Debt to equity
0.75
DRIO's short-term assets ($22.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DRIO's long-term liabilities ($31.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DRIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DRIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$2.3M
Financing
$0.0
DRIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DRIO vs Diagnostic & Research Stocks
Dariohealth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.